The Deal
Sunday, November 22, 
5:43 am

Biogen Idec slate snubs Icahn's nominees

  Share     E-Mail    Discussion    Print Story
icahn.jpgBiogen Idec Inc. of Cambridge, Mass., said Thursday it would nominate four directors for the upcoming annual shareholder meeting, none of which are part of dissident investor Carl Icahn's nomination slate.

Continue reading below

Also on Dealscape

The firm's decision is a rejection of Icahn, who tried to maneuver the company into a sale last fall, to no avail. Claiming Biogen executives sabotaged the sale process, Icahn is pressing a proxy fight and suing to gain access to documents, including board meeting minutes, to shed light on the failed auction.

Three of Biogen's nominees are returning directors, and one, former investment banker and biotech veteran Stelios Papadapoulos, would be new to the company. A date for the annual meeting has not been announced. - Alex Lash

See press release
See earlier story from Dealscape
See earlier story from TheDeal.com
See Dealwatch: Carl Icahn





Post a comment





The Deal Pipeline

Deal Video


Inside The Deal: Avaya Inc.'s Mohamad Ali on the company's next target.


More video...

Crisis On Wall Street
Technology
Deals of The Decade

Community

Industry Insight

Managing your shareholder base

Growth companies and their PE sponsors should be wary of the pitfalls that arise when they layer on tiers of preferred stock.


Industry Insight

Easing the stress of distressed M&A

Corporate buyers face numerous complexities when trying to identify the right moment to purchase a distressed asset.


Editor's Note

Editor's letter: Nov. 16, 2009

Beneath the veneer of Wall Streeters beats the same heart, stirred by the same determinants of behavior.


footspacer.jpg footspacer.jpg footspacer.jpg footspacer.jpg footspacer.jpg


©Copyright 2009, The Deal, LLC. All rights reserved. Please send all technical questions, comments or concerns to the Webmaster.